Company Filing History:
Years Active: 1997
Title: The Innovations of Stanislaw Szala
Introduction
Stanislaw Szala is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of biotechnology, particularly in the development of tumor-associated antigens. His work has implications for cancer research and treatment.
Latest Patents
Stanislaw Szala holds a patent for "DNA and polypeptide for tumor-associated antigen CO-029." This invention describes the human tumor-associated antigen CO-029, which is defined as a monoclonal antibody-defined, 27-34 kDa cell surface glycoprotein. The patent details a full-length cDNA clone for CO-029, which, when transiently expressed in COS cells, directs the synthesis of an antigen reactive with monoclonal antibody CO-029 in mixed hemadsorption and immunoblot assays. Sequence analysis indicates that CO-029 is part of a family of cell surface antigens, which includes the melanoma-associated antigen ME491, the leukocyte cell surface antigen CD37, and the Sm23 antigen of the parasitic helminth Schistosoma mansoni.
Career Highlights
Stanislaw Szala is affiliated with The Wistar Institute, where he conducts his research. His work at this prestigious institution has allowed him to explore innovative solutions in cancer biology. His contributions have been recognized within the scientific community, particularly for their potential impact on cancer diagnostics and therapeutics.
Collaborations
Some of his notable coworkers include Alban J Linnenbach and Hilary Koprowski. Their collaborative efforts have further advanced the research in tumor-associated antigens and their applications in medicine.
Conclusion
Stanislaw Szala's work exemplifies the intersection of innovation and medical research. His patent for the tumor-associated antigen CO-029 highlights his contributions to the field of biotechnology. His ongoing research at The Wistar Institute continues to pave the way for advancements in cancer treatment.